[Chemotherapy of pulmonary carcinoma. Considerations and a proposal of a system of the evaluation of clinical course].
With absolutely no attempt to reject chemotherapy of lung cancer as useless, particularly now that extremely effective antiblastic products are available, it is however suggested that we should think carefully before adopting treatments of doubtful efficacy that may prolong the patient's life but also increase his suffering in that they produce extremely unpleasant side effects without having much influence on the basic symptoms. In such cases it may be the physician's painful duty to withhold treatment.
D000230:Adenocarcinoma / Q000188:drug therapy; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002277:Carcinoma / Q000188:drug therapy*; D018288:Carcinoma, Small Cell / Q000188:drug therapy; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008875:Middle Aged
D000970:Antineoplastic Agents
Chemioterapia nel carcinoma polmonare. Considerazioni e proposta di un indice di valutazione dell'evoluzione clinica.